Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,901–12,000 of 15,747
Yoshimoto, N., YANAGI, A., Takayama, S., Sakamoto, M., Tomoda, K., Ishikawa, K., Kawate, A., Takayama, S., Yamashita, M., Yamamoto, S., et al. (2022) · In Vivo · doi:10.21873/invivo.12921 · Cited by 3
Novikov, M., Hasanpourghadi, M., Ambrose, R., Chekaoui, A., Newman, D., Giles‐Davis, W., Xiang, Z., Zhou, X., & Ertl, H. C. J. (2022) · SSRN Electronic Journal · doi:10.1101/2022.02.23.481620 · Cited by 1
“11,12 The efficacy of the Ad vector vaccines varies; the one dose J&J vaccine shows 67% protection against disease, 13 the chimpanzee-derived Ad (AdC) vaccine from AstraZeneca that uses the same vector twice has an efficacy of 76% 14 while the two dose Sputnik V vaccine that primes with one human…”
BackgroundChoi, S. J., Lee, W., Kim, S. C., Jo, H.-Y., Park, H., Kim, H. B., Park, W., Park, S. H., Ko, J., & Lee, J. S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.019 · Cited by 2
Katte, R. H., Ao, Y., Wang, X., Han, Y., Zhong, G., Ghimire, D., Florence, J., Tucker, T. A., & Lu, M. (2024) · Viruses · doi:10.3390/v16030391 · Cited by 3
DNA nanodevices in nanomedicine and therapeutics
Vaswani, P., Hema Naveena, A., & Bhatia, D. D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90984-6.00001-5 · Cited by 2
Pharmaceutical contributions to personalized medicine
Perlmutter, R. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0019 · Cited by 5
Combinatorial mRNA vaccination enhances protection against SARS-CoV-2 delta variantPreprint
Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M., Tang, J., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., Liu, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.08.471664 · Cited by 2
CURRENT OVERVIEW OF COVID-19 VACCINATION PROCESS IN SERBIA
Catić−Djordjević, A., STEFANOVIĆ, N. Z., Spasić, A., Damnjanović, I., Radovanović, R. V., Djindjić, B., & Pavlovič, D. (2021) · Acta Medica Medianae · doi:10.5633/amm.2021.0303 · Cited by 2
“This is consistent with findings from other studies (5, 8, 13, 14).”
Inmunología en COVID-19; mucho más allá del diagnóstico de la infección o de la vacunación
Egri, N., & Juan, M. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.11.001 · Cited by 3
COVID‐19: Laboratory/Serologic Diagnostics
Chin, D., Eibschutz, L. S., Sobczyk, J., Azami, M., Repajic, M., & Dubé, M. P. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch3 · Cited by 2
mRNA vaccines: Why is the biology of retroposition ignored?
(2021) · doi:10.31219/osf.io/uwx32 · Cited by 2
Algaissi, A. A., Alamer, E., Jeraiby, M., Alomaish, A. R., Elrhima, O. A., Qumayi, S., Qasir, N. A., Areeshi, H., Masmali, A., & Alhazmi, A. (2022) · Saudi Medical Journal · doi:10.15537/smj.2022.43.6.20220135 · Cited by 2
Warren, J. L., Sundaram, M. E., Pitzer, V. E., et al. (2023) · Epidemiology · doi:10.1097/ede.0000000000001690 · Cited by 2
Fang, X., Tao, G., Zhou, H., & Zhou, Y. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102632 · Cited by 3
Immune response to SARS-CoV-2 variants after immunization with different vaccines in Mexico
Garay, E., Whelan, S. P. J., DuBois, R. M., O’Rourke, S. M., Salgado-Escobar, A. E., Muñoz‐Medina, J. E., Arias, C. F., & López, S. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824000219 · Cited by 3
“In clinical trials, BNT162b2, Sputnik V, and ChAdOx1-S vaccines showed great efficacy in preventing hospitalization of patients infected with the parental Wuhan strain of the virus [19 – 21].”
BackgroundSpatiotemporal characteristics of the SARS-CoV-2 Delta wave in North Carolina
Pang, C. J., & Delamater, P. L. (2023) · Spatial and Spatio-temporal Epidemiology · doi:10.1016/j.sste.2023.100566 · Cited by 2
Follow‑up care after COVID-19 and its related concerns
Radvan, M., Bartečků, E., Sýkorová, Ľ., Pařízková, R., Richter, S., Kamenik, M., Koc, L., & Kala, P. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.004 · Cited by 2
Immunological efficacy and tolerability of vaccination in patients with noncommunicable diseases
Drapkina, O. M., Мамедов, М. Н., Kutsenko, V. A., et al. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4890 · Cited by 2
mRNA Vaccines: Immunology and Present and Future Potential
Khan, O. F., Couture‐Senécal, J., Lau, Y. M. A., Oproescu, A.-M., Pang, J., Tilstra, G., & Walz, B. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-62772-9_5 · Cited by 2
Reacciones adversas y vacunación contra COVID-19 en adultos diabéticos.
Quimis, J. A. I., Quimis, J. J. I., & Macías, C. Z. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.1.2023.1283-1304 · Cited by 1
Adverse events post-BNT162b2 vaccination in Japanese children
Okabe, H., Hashimoto, K., Asano, Y., Sato, M., Nakatsu, H., Ono, T., Shibukawa, Y., Sakai, N., Onishi, N., Oda, S., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128167 · Cited by 3
Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
Ávila, J., Degirmenci, H. B., Contreras-Chavez, P., Battinelli, E. M., & Fleisher, J. (2023) · Case Reports in Hematology · doi:10.1155/2023/7877536 · Cited by 2
Chen, Z., Mu, X., Wang, X., Zhang, L., Liu, G., Zheng, J., & Ding, F. (2023) · Vaccines · doi:10.3390/vaccines11111710 · Cited by 2
Advances and Challenges in COVID-19 Vaccination in Latin American: A public health perspective
Fernandez‐Guzman, D., Chávez-Cruzado, E., Díaz-Vélez, C., Gálvez-Olortegui, T., la Rosa, E. V.-D., Rodriguez-Morales, A. J., & Gálvez-Olórtegui, J. (2022) · Infectio · doi:10.22354/24223794.1094 · Cited by 2
Vacunas SARS-CoV-2: evolución y escape
Rivero, R., Marco González, T., & Mattar, S., V (2021) · Revista Mvz Córdoba · doi:10.21897/rmvz.2372 · Cited by 1
Ateş, A. K., & Er, E. (2024) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ad851e · Cited by 2
Dinagde, D. D., Feyisa, G. T., Lahole, B. K., et al. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02399 · Cited by 2
ViralVacDB: A manually curated repository of viral vaccines
Tripathi, S., Sharma, N., Naorem, L. D., & Raghava, G. P. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103523 · Cited by 3
Gim, H., Oh, S.-Y., Lee, H., Lee, S., Seo, H., Park, Y., & Park, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416958 · Cited by 4
Assessing the potential seasonality of COVID-19 dynamic in Africa: a mathematical modeling study
Montcho, Y., Amoussouvi, K. T., Atchadé, M. N., Salako, K. V., Hounkonnou, M. N., Wolkewitz, M., & Kakaï, R. G. (2025) · Modeling Earth Systems and Environment · doi:10.1007/s40808-024-02236-4 · Cited by 2
“Unfortunately, their effectiveness decay over time, and even vaccinated people can become infected after a certain period (Polack et al. 2020).”
COVID-19 booster enhances IgG mediated viral neutralization by human milk in vitro
Valcarce, V., Stafford, L. S., Neu, J., Parker, L. A., Vicuna, V., Cross, T. R., D'Agati, O. M., Diakite, S., Haley, A., Feigenbaum, J., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1289413 · Cited by 3
Will the large‐scale vaccination succeed in containing the COVID‐19 pandemic and how soon?
Zhao, S., Sha, T., Xue, Y., Wu, C.-I., & Chen, H. (2021) · Quantitative Biology · doi:10.15302/j-qb-021-0256 · Cited by 4
van den Berg, J. M., Blom, M. T., Overbeek, J. A., Remmelzwaal, S., Herings, R. M. C., & Elders, P. J. M. (2025) · Vaccines · doi:10.3390/vaccines13060564 · Cited by 3
Osei, F., Tudzi, K. K., Othol, I. O., Segbefia, S. P., Prah, D. A., Nii, E., Pobee, A. N. A., Darko, O. N. O., Brenko, T., Teye‐Adjei, D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643083 · Cited by 3
Kızılkılıç, E. K., Kılboz, B. B., & Üçler, S. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_1002_22 · Cited by 3
“[7] In BNT162b2 clinical trials (manufactured by BioNTech and Pfizer), a higher incidence of headache was noted after the second dose than the first dose, with approximately 52% of patients reporting mild to moderate headaches.[8]”
MethodYıldırım, S., Kıraklı, C., Özdemir, Y., Tosun, S. Y., Ermin, S., Polat, G., Yılmaz, C., Bilaçeroğlu, S., Salık, B., Komurcuoglu, B. E., et al. (2024) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.18342 · Cited by 3
Zhang, E., Nguyen, T. H. O., Allen, L. F., et al. (2022) · medRxiv · doi:10.1101/2022.12.13.22283434 · Cited by 2
Ogo, N., Ikegame, S., Hotta, T., Kan‐o, K., Yoneshima, Y., Shiraishi, Y., Tsubouchi, K., Tanaka, K., & Okamoto, I. (2024) · Cureus · doi:10.7759/cureus.61470 · Cited by 2
“Effective vaccination subsequently reduced the number of symptomatic infectious events and their severity [3], although coronavirus disease 2019 (COVID-19) can still be fatal among high-risk groups such as the elderly, the immunocompromised, and individuals with chronic respiratory disease [4].”
BackgroundKaraaslan, H. B. G., Bertecene, N., Mustu, U., et al. (2023) · Allergologia et Immunopathologia · doi:10.15586/aei.v51i3.800 · Cited by 2
Gender difference in COVID-19 vaccination; recent concepts
Soleimani, P., Jahantigh, H. R., & Yadollahifarsani, S. (2022) · Journal of Parathyroid Disease · doi:10.34172/jpd.2022.11167 · Cited by 2
Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report
Lim, J., Paek, J. H., Shin, H. C., Park, W. Y., Jin, K., Choe, M., Han, S., & Kim, Y. (2024) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2024.13.1.68 · Cited by 3
“Despite widespread worry about the unexpected side effects of this vaccine, its efficacy and safety as a COVID-19 vaccine were revealed to be acceptable in a large population-based clinical trial [2].”
BackgroundThe risk of COVID-19 transmission upon return to sport: a systematic review
Jia, L., Huffman, W. H., Cusano, A., Trofa, D. P., Li, X., Kelly, J. D. A., & Parisien, R. L. (2022) · The Physician and Sportsmedicine · doi:10.1080/00913847.2022.2035197 · Cited by 2
Sudden Hearing Loss Waves: The Effect of COVID-19 Infection and Vaccination on the Inner Ear
Tawk, K., Tawk, A., & Abouzari, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_15 · Cited by 3
Mohammed, A., Ibrahim, N. A., & Basher, N. S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152947 · Cited by 2
Chamie-Quintero, J. J., Hibberd, J. A., & Scheim, D. E. (2022) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/h7zbg · Cited by 2
Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan
Matsumoto, N., Sasaki, A., Kadowaki, T., Mitsuhashi, T., Takao, S., & Yorifuji, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126156 · Cited by 4
ANCA Glomerulonephritis after COVID-19 and post-COVID-19 vaccination – current state of knowledge
Tomasik, J. M., Sajdak, P., Ziajor, S., Turski, M., Bednarski, A., Dębik, M., Stodolak, M., Szydłowski, Ł., Krużel, A., Żurowska, K., et al. (2024) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/186198 · Cited by 2
“A favourable safety profile was observed during the first phase of the BNT162b2 study, confirmed in the phase 2/3 part of the trial, and was similar to that of other viral vaccines [16].”
ResultRethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Blanco, J., Trinité, B., & Puig‐Barberà, J. (2025) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70076 · Cited by 4
“%) for vaccine BNT1626b [15].”
A mirror in fiction: drawing parallelisms between Camus’s La Peste and COVID-19
Pérez-Romero, C. (2021) · Medical Humanities · doi:10.1136/medhum-2021-012156 · Cited by 8
“Some of these vaccines are mRNA- based (Baden et al. 2021; Polack et al. 2020), while others use a viral vector (Bos et al. 2020; Voysey et al. 2021).”
BackgroundInfluentialCegolon, L., & Filon, F. L. (2024) · Vaccines · doi:10.3390/vaccines12030254 · Cited by 2
Bruno, R., McCullough, P. A., Vila, T. F. I., Henrion‐Caude, A., García-Gasca, T., Zaitzeva, G. P., Priester, S., Albarracín, M. J. M., Sousa‐Escandón, A., Mirones, F. L., et al. (2021) · doi:10.22541/au.162136772.22862058/v2 · Cited by 2
“Most trials also excluded pregnant and lactating volunteers, as well as those with chronic and serious conditions such as tuberculosis, hepatitis C, autoimmunity, coagulopathies, cancer, and immune suppression [16-29], although these recipients are now being offered the vaccine under the premise of safety.”
BackgroundLee, M.-K. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab011 · Cited by 2
Mahmud, N., Reinisch, W., Patel, M., et al. (2022) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000554 · Cited by 2
“DISCUSSION In the Pfizer vaccine trial, the serious adverse events which were higher among those who received the vaccine vs placebo were acutemyocardial infarction and cerebrovascular accident (5).”
BackgroundShould people with chronic liver diseases be vaccinated against COVID-19?
Chen, L., Zeng, Q., Gong, Y., & Liang, F.-L. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i26.7959 · Cited by 2
Kapoor, R., Standaert, B. A., Pezalla, E. J., Demarteau, N., Sutton, K. A., Tichy, E., Bungey, G., Arnetorp, S., Bergenheim, K., Darroch-Thompson, D., et al. (2023) · Vaccines · doi:10.3390/vaccines11020377 · Cited by 2
“Boosters were not considered to lead to any severe adverse events based on the findings from clinical trials [14,47,48].”
BackgroundMunjal, T., Batts, S. A., Gombar, S., & Stanković, K. M. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1637870 · Cited by 2
ALi, A., Alamri, A. M., Mishra, V. K., Utegenova, A., Askarova, G., Baiduissenova, A., & Dusmagambetova, A. (2026) · BMC Immunology · doi:10.1186/s12865-025-00795-4 · Cited by 7
“By harnessing these cutting-edge approaches, we can pave the way for a more robust and targeted vaccine against MTB, ultimately contributing to a world free from TB. Recently, mRNA vaccines have been instrumental in combating COVID-19 [106, 107].”
COVID-19 vaccines: what happened to evidence-based medicine?
Quek, E., & Tahir, H. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0047 · Cited by 2
SARS-CoV-2-Impfungen – Was muss der Nephrologe wissen?
Heine, G. H., Becker, S. L., Scheuer, A. L., & Schirmer, S. H. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1375-4471 · Cited by 2
Multi-step engineered adeno-associated virus enables whole-brain mRNA deliveryPreprint
Bai, W., Yang, D., Zhao, Y., Li, G., Liu, Z., Xiong, P., Quan, H., Wu, X., Chen, P. R., Kong, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.04.597261 · Cited by 4
Gaggl, M., Aschauer, C., Aigner, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969193 · Cited by 2
“In early 2021 regulatory authorities approved several SARSCoV-2 vaccinations targeting the spike protein expressed at the virus surface (3, 4).”
BackgroundMallory, M. L., Munt, J. E., Narowski, T. M., Castillo, I. N., Cuadra, E., Pisanic, N., Fields, P., Powers, J. M., Dickson, A. M., Harris, R., et al. (2023) · medRxiv · doi:10.1101/2023.04.03.23287498 · Cited by 2
Hirsch, O., & Rinner, C. (2023) · doi:10.32920/24595017 · Cited by 3
Tongsengkee, N., Surasombatpattana, S., Tanomkiat, W., Siripaitoon, P., Kositpantawong, N., Kanchanasuwan, S., Navasakulpong, A., Pinpathomrat, N., Dechaphunkul, A., Phongphithakchai, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041388 · Cited by 2
Lessons from mycobacteria: development and design of Mincle-targeting adjuvants
Ishizuka, S., & Yamasaki, S. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101526 · Cited by 2
Leontieva, G., Gupalova, T. V., Desheva, Y. A., Kramskaya, T. A., Bormotova, E., Koroleva, I. V., Kopteva, O. S., & Suvorov, A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010215 · Cited by 2
“Approved vaccines have demonstrated favorable outcomes by mitigating the risks of severe illness, hospitalizations, and fatalities [13–16].”
BackgroundCOVID-19 vaccination and critical care capacity: Perilous months ahead
Reperant, L. A., & Osterhaus, A. D. M. E. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.035 · Cited by 1
COVID-19 Vaccine Hesitancy and Women’s Reproductive Health Concerns
Wenande, B., Tessier, K., Westberg, S. M., Grundman, R. E., & Larsen, K. (2026) · American Journal of Health Promotion · doi:10.1177/08901171261426781 · Cited by 2
Batho, C. A. P., Hudson, J. E., & Wilson, C. H. (2025) · Biochemical Society Transactions · doi:10.1042/bst20243001 · Cited by 3
The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection
Xue, V. W., Wong, S. C. C., Li, B., & Cho, W. C. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218083 · Cited by 2
“BNT162b2, that yield nonimmunogenic vector and achieve efficient IVT by replacing uridine with N(1)-methylpseudouridine (m1Ψ) [33].”
BackgroundA brief history of the COVID-19 pandemic: perspectives in risk science and data analytics
Trump, B. D., Keenan, J. M., & Linkov, I. (2025) · Journal of Risk Research · doi:10.1080/13669877.2025.2569437 · Cited by 2
Bando, T., Ikematsu, H., Kawai, N., Shibao, K., Mizuguchi, M., Amemiya, T., Tsuchiya, S., Oribe, Y., Lee, W. J., Maeda, T., et al. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102798 · Cited by 2
Points-to-consider: the mRNA vaccine reflection paper
Yamaguchi, T., Ogawa, T., Tsuyoshi, A. N. D. O., Yoshida, S., Sakurai, A., Maki, K., & Araki, Y. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2023-007 · Cited by 3
A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab
Jarzębska, N. T., Frei, J., Mellett, M., Kündig, T. M., Pascolo, S., & Reichmuth, A. M. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_11 · Cited by 3
Walach, H., & Klement, R. J. (2024) · Journal of Scientific Exploration · doi:10.31275/20243249 · Cited by 4
Multi‐readout thermoplasmonic biosensor for rapid detection of oligonucleotides
Sforza, M. L., Marinis, E. D., Masi, A., Nervi, C., Sio, L. D., & Petronella, F. (2025) · View · doi:10.1002/viw.20240123 · Cited by 4
Pageaud, S., Eyraud-Loisel, A., Bertoglio, J. P., Bienvenüe, A., Leboisne, N., Pothier, C., Rigotti, C., Ponthus, N., Gauchon, R., Gueyffier, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10122033 · Cited by 2
“In 2020 and 2021, clinical trials reported that their efficacy in avoiding severe forms of the disease caused by the Alpha variant was 75% [11] and even 94% [12,13].”
Thakur, K. T., Tamborska, A., Wood, G. K., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844148 · Cited by 2
COVID-19 Vaccine Impacts in Saudi Arabia: A Cross-Sectional Study
Mohammedsaeed, W. M., Alrashidi, H., Alsharif, S. M., et al. (2023) · Cureus · doi:10.7759/cureus.40460 · Cited by 2
“Nevertheless, in the clinical context, there were some patients who became infected with COVID-19 despite having received the vaccination, while there were other patients who were safeguarded by their prior infection [6-8].”
BackgroundÁngeles-Martínez, J., Monroy-Muñoz, I. E., Muñoz‐Medina, J. E., Fernandes-Matano, L., Salas-Lais, Á. G., Hernández-Cueto, M. D. L. Á., Bravo-Flores, E., León‐Juárez, M., Santacruz-Tinoco, C. E., & Montes-Herrera, D. (2024) · Vaccines · doi:10.3390/vaccines12010088 · Cited by 4
“…decreased, showing that the vaccines confer protection against the severity of COVID-19 in all participants, which is similar to other studies, where the efficacy of mRNA vaccines against SARS-CoV-2 does not differ between people with obesity compared to; that in people without obesity [40,41].”
ResultFeng, M., Tian, L., & Zhou, C. (2021) · SSRN Electronic Journal · doi:10.1101/2021.10.11.21264836 · Cited by 2
“Our model is calibrated against the clinical characteristics of COVID-19 progression and transmission, real contact data between different age groups, as well as the vaccine efficacy and realistic continuous implementation of vaccinations [2,23].”
MethodImpact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects
Alshehri, S., Almutawif, Y. A., & Khan, N. U. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09783-1 · Cited by 3
“Polack et al. and Monin et al. also conducted an extensive cohort study reporting that the Pfizer-BioNTech vaccine is safe and well tolerated, with only mild to moderate adverse events limited to mild-to-moderate pain at the injection site, fatigue, and headache [33, 34].”
Ando, W., Horii, T., Jimbo, M., Uematsu, T., Atsuda, K., Hanaki, H., & Otori, K. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.985494 · Cited by 2
IgA Vasculitis following AstraZeneca/Oxford COVID-19, case report.
Alzoabi, N. M., Alqahtani, J. M., Algamdi, B., Alghamdi, N., Ahmad, A. K., Alkaltham, G. K. I., Beidas, T., & Alakloby, O. M. (2023) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v94i6.12959 · Cited by 2
“All the vaccines showed a safe and efficacious profile with minimal side effects which include mild to moderate soreness at the injection site, fever, exhaustion, body aches, and headache (2,3).”
BackgroundComparison of COVID-19 vaccine prioritization strategiesPreprint
Chapman, L. A. C., Shukla, P. D., Rodríguez-Barraquer, I., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-602122/v1 · Cited by 2
Niazi, S. K. (2024) · Discover Medicine · doi:10.1007/s44337-024-00107-6 · Cited by 2
Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
Laporte, B. E. P., Laporte, E. G. J., Aarestrup, P. F., Aarestrup, M. F., & Aarestrup, F. M. (2022) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0042-1745788 · Cited by 5
Yahya, M. Q., Hamad, Z. S., & Kasim, S. M. (2021) · Global Journal of Public Health Medicine · doi:10.37557/gjphm.v3i2.99 · Cited by 3
COVID-19-Impfung unter Psychopharmakotherapie
Seifert, J., Heck, J., Eckermann, G., Singer, M., Bleich, S., Grohmann, R., & Toto, S. (2021) · Psychiatrische Praxis · doi:10.1055/a-1531-4460 · Cited by 2
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Šali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2023) · eLife · doi:10.7554/elife.89423.1 · Cited by 3
Laha, S., & Chatterjee, R. (2021) · Future Virology · doi:10.2217/fvl-2021-0062 · Cited by 2
“Among the frontrunners that have gained approval include the mRNA-based vaccines named BNT162b2 [40] and mRNA-1273 [41] manufactured by ModernaTX Inc.; CoronaVac [9], which utilize an inactivated form of the virus; Sputnik V [42,43].”
BackgroundAutorización de uso de emergencia primera vacuna RNA para COVID-19 en Chile
Andresen, M., Corrales, R., Gallardo, J., Noriega, V., Sánchez-Montoya, E., & Weinstein, C. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020001201711 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.